A retrospective TriNetX study reports that people with hidradenitis suppurativa, obesity or type 2 diabetes and recorded exposure to GLP-1 receptor agonists or Tirzepatide had different two-year outcomes from matched users of other metabolic medicines. The authors report lower observed all-cause mortality and major cardiovascular-event risks, alongside lower recorded psychiatric outcomes. These are associations in medical records, not evidence that the exposure caused the differences.
Hidradenitis suppurativa, or HS, is a chronic inflammatory skin condition that is frequently seen alongside obesity and type 2 diabetes. The investigators used the US Collaborative Network in TriNetX to compare adults with HS and either metabolic condition. People in the exposed group had received a GLP-1RA or Tirzepatide for at least a year; controls received other systemic antidiabetic or anti-obesity agents. People with prior bariatric surgery were excluded.
How the authors built the cohorts
Before matching, the exposed group contained 8,564 people and the comparison group 6,299. The authors applied one-to-one propensity-score matching separately for outcome categories, then assessed outcomes across two years. Propensity scores can align measured variables, but they cannot randomize treatment or remove every difference in severity, access to specialist care, behaviour, adherence or record completeness.
The comparison included mortality, cardiovascular, rheumatologic, metabolic, psychiatric and non-communicable inflammatory outcomes. Cox regression, sensitivity analyses and benchmark comparisons were also used. This is a broad outcome framework, which makes cautious interpretation especially important: a record-based association can reflect exposure, baseline health, surveillance intensity or factors not captured in the database.
What the study recorded
After matching, the authors report lower all-cause mortality in the GLP-1RA/Tirzepatide group, with a hazard ratio of 0.24 and a 95% confidence interval of 0.145 to 0.395. Major adverse cardiovascular events had a reported hazard ratio of 0.61, with a 95% confidence interval of 0.500 to 0.749. Stroke and heart-failure outcomes were also lower in the reported analysis.
For psychiatric outcomes, the paper reports hazard ratios of 0.78 for depression, 0.38 for suicidal ideation and 0.58 for substance-use disorder. It also reports statistically similar rheumatologic and non-communicable inflammatory outcomes. At the same time, the exposed group had higher recorded risks of hyperlipidaemia, metabolic dysfunction-associated steatotic liver disease and nausea or vomiting. The reported hazard ratios were 1.25, 1.37 and 1.31, respectively.
Those results should not be converted into a therapeutic claim about Tirzepatide. The exposure category combines several GLP-1 receptor agonists with Tirzepatide, and the study does not establish a separate estimate for each. It also does not show why individual outcomes differed. Coding practice, detection patterns and residual confounding can all affect a large electronic-record comparison.
Why HS makes the question interesting
HS has inflammatory, dermatological and metabolic dimensions, so a database study can ask whether a metabolic exposure is associated with outcomes beyond a single laboratory measure. But observational breadth is not mechanistic proof. The article does not show that a GLP-1 pathway altered HS biology, and it does not establish a change in HS lesion activity as a primary causal effect.
Tirzepatide is a dual GIP/GLP-1 agonist. The Tirzepatide research buyer guide is a research-material reference, not clinical direction. Retatrutide is a separate compound with a different receptor profile; its context belongs in the Retatrutide research reference hub.
The appropriate takeaway
The size and matching methods make this a useful real-world signal. Its limitations are equally central: retrospective design, combined exposures, reliance on coded records and potential unmeasured confounding. Independent datasets, prospective designs and studies with HS-specific endpoints would be needed before making stronger claims.
Peptra Labs material remains within a Research Use Only boundary. For broad context, see Best Research Peptides 2026, which is not evidence for the outcomes in this cohort.
In short, the authors observed different two-year outcome patterns among matched people with HS and metabolic disease who had recorded GLP-1RA or Tirzepatide exposure. The study is valuable for hypothesis generation, while its design prevents it from proving causation or supporting individual clinical decisions.
References
- Brouer IC, Zani A, Olbrich H, et al. GLP-1 receptor agonists and tirzepatide are associated with reduced mortality, cardiovascular, and psychiatric risks in patients with hidradenitis suppurativa and type 2 diabetes and/or obesity: a retrospective cohort study. Frontiers in Medicine. 2026. PubMed
- Austin PC. An introduction to propensity score methods for reducing confounding in observational studies. Multivariate Behavioral Research. 2011. Article
- National Institute of Arthritis and Musculoskeletal and Skin Diseases. Hidradenitis suppurativa. NIAMS overview
The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.
